pioglitazone and Liver Steatosis studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

Excerpt	Relevance	Reference
" Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3."	9.15	Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011)
"Six months of pioglitazone treatment in patients with NASH is associated with weight gain that is attributable to an increase in adipose tissue mass and not to water retention."	9.12	Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. ( Balas, B; Belfort, R; Cusi, K; Darland, C; Finch, J; Gastaldelli, A; Harrison, SA; Schenker, S, 2007)
"In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis."	9.12	A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. ( Balas, B; Bannayan, GA; Belfort, R; Berria, R; Brown, K; Cusi, K; Darland, C; DeFronzo, R; Dwivedi, S; Finch, J; Fincke, C; Gastaldelli, A; Hardies, J; Harrison, SA; Havranek, R; Ma, JZ; Pulcini, J; Schenker, S; Tio, F, 2006)
"The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats."	7.91	Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019)
"Nutritional approaches are sought to overcome the limits of pioglitazone in metabolic syndrome and non-alcoholic fatty liver disease."	7.78	Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. ( Fujimoto, M; Fujimoto, T; Gershwin, ME; Selmi, C; Shimada, Y; Tsuneyama, K, 2012)
" Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients."	7.78	The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ( Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H, 2012)
" We investigated the effects of curcumin on fructose-induced hypertriglyceridemia and liver steatosis and explored its preventive mechanisms in rats."	7.76	Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats. ( Hu, QH; Kong, LD; Li, JM; Li, YC, 2010)
" Using a murine model of steatohepatitis (mice fed a diet deficient in methionine and choline-MCD diet), we tested the effects of the insulin-sensitising, PPARgamma agonist drug pioglitazone (PGZ) on systemic and intrahepatic insulin sensitivity and on liver pathology."	7.74	Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. ( Horsmans, YJ; Lebrun, VA; Leclercq, IA; Stärkel, P, 2007)
" Pioglitazone can attenuate insulin resistance and biochemical and histological injury in high fat-induced fatty liver in rats."	7.73	Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. ( Li, YM; Xu, GY; Xu, L; Xu, P; Yu, CH; Zhang, XG, 2006)
" Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance."	7.72	Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004)
"Pioglitazone was well tolerated and no one discontinued due to side effects."	6.80	Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. ( Benator, D; Chairez, C; Hadigan, C; Kleiner, DE; Kovacs, JA; Matthews, L; McManus, M; Morse, CG; Nettles, MJ; Zemanick, K, 2015)
"Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy."	6.71	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. ( Doo, E; Freedman, RJ; Ghany, M; Heller, T; Hoofnagle, JH; Kleiner, DE; Liang, TJ; Lutchman, G; Park, Y; Premkumar, A; Promrat, K; Soza, A; Uwaifo, GI; Yanovski, JA, 2004)
" The suggestion of this Expert Panel is that, pending forthcoming randomized clinical trials, physicians should consider using a PPARgamma agonist, such as pioglitazone, or, statin use in those with NAFLD/NASH at high CVD or HCC risk, alone and/or preferably in combination with each other or with ezetimibe, for the primary or secondary prevention of CVD, and the avoidance of cirrhosis, liver transplantation or HCC, bearing in mind that CVD is the main cause of death in NAFLD/NASH patients."	6.55	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. ( Alexandrides, TK; Athyros, VG; Bilianou, H; Cholongitas, E; Doumas, M; Elisaf, MS; Ganotakis, ES; Germanidis, G; Giouleme, O; Goudevenos, J; Karagiannis, A; Karvounis, C; Katsiki, N; Kotsis, V; Kountouras, J; Liberopoulos, E; Mantzoros, C; Mikhailidis, DP; Pitsavos, C; Polyzos, S; Rallidis, LS; Richter, D; Tsapas, AG; Tselepis, AD; Tsioufis, K; Tziomalos, K; Tzotzas, T; Vasiliadis, TG; Vlachopoulos, C, 2017)
"Nonalcoholic steatohepatitis (NASH), which is considered the hepatic manifestation of the metabolic syndrome is an increasingly cause of chronic liver disease in Japan."	6.43	[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. ( Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K, 2006)
"Pioglitazone also mitigated most of the steatohepatitis-related changes, however, memantine was more effective in most of the studied parameters."	5.91	A novel approach to repositioning memantine for metabolic syndrome-induced steatohepatitis: Modulation of hepatic autophagy, inflammation, and fibrosis. ( Abdel-Ghanyª, RH; Alsemehᵇ, AE; Elgharbawyª, AS; Metwallyª, SS; Zakariaª, EM, 2023)
"Pharmacotherapy in NAFLD is not well validated, particularly combination therapy."	5.40	Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014)
"Non-alcoholic steatohepatitis (NASH) may progress to liver cirrhosis, and NASH patients with liver cirrhosis have a risk of development of hepatocellular carcinoma."	5.32	Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. ( Kawaguchi, K; Okita, K; Omori, K; Sakaida, I; Takami, T; Tsuchiya, M, 2004)
" Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3."	5.15	Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011)
"In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis."	5.12	A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. ( Balas, B; Bannayan, GA; Belfort, R; Berria, R; Brown, K; Cusi, K; Darland, C; DeFronzo, R; Dwivedi, S; Finch, J; Fincke, C; Gastaldelli, A; Hardies, J; Harrison, SA; Havranek, R; Ma, JZ; Pulcini, J; Schenker, S; Tio, F, 2006)
"Six months of pioglitazone treatment in patients with NASH is associated with weight gain that is attributable to an increase in adipose tissue mass and not to water retention."	5.12	Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. ( Balas, B; Belfort, R; Cusi, K; Darland, C; Finch, J; Gastaldelli, A; Harrison, SA; Schenker, S, 2007)
" Current treatment strategies aim to improve insulin resistance via weight loss and exercise, improve insulin sensitivity by the use of insulin-sensitizing agents (for example, pioglitazone) and reduce oxidative stress by the use of antioxidants, such as vitamin E."	4.87	Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. ( Adams, LA; Smith, BW, 2011)
"The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats."	3.91	Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019)
" However, liraglutide induced weight loss, improved glycaemic control, reduced ALT and AST and showed some beneficial effects upon steatosis and lobular inflammation."	3.91	Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. ( Brockbank, S; Bruun, MF; Cruwys, S; Daniels, SJ; Detlefsen, S; Hein, P; Henriksen, K; Hjuler, ST; Karsdal, MA; Leeming, DJ, 2019)
" Mice with diet-induced obesity were treated with the PPARγ or PPARα agonist, pioglitazone or fenofibrate, respectively."	3.83	Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver. ( Jia, WP; Wang, C; Zhang, ML; Zhong, Y; Zhu, YX, 2016)
"Pioglitazone, a selective ligand of peroxisome proliferator-activated receptor gamma (PPARγ), is an insulin sensitizer drug that is being used in a number of insulin-resistant conditions, including non-alcoholic fatty liver disease (NAFLD)."	3.81	Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice. ( Hou, S; Huan, Y; Jia, C; Jiang, Q; Li, C; Liu, Q; Liu, S; Shen, Z; Sun, S; Wang, Y, 2015)
" Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients."	3.78	The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ( Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H, 2012)
"Nutritional approaches are sought to overcome the limits of pioglitazone in metabolic syndrome and non-alcoholic fatty liver disease."	3.78	Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. ( Fujimoto, M; Fujimoto, T; Gershwin, ME; Selmi, C; Shimada, Y; Tsuneyama, K, 2012)
" We investigated the effects of curcumin on fructose-induced hypertriglyceridemia and liver steatosis and explored its preventive mechanisms in rats."	3.76	Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats. ( Hu, QH; Kong, LD; Li, JM; Li, YC, 2010)
" Using a murine model of steatohepatitis (mice fed a diet deficient in methionine and choline-MCD diet), we tested the effects of the insulin-sensitising, PPARgamma agonist drug pioglitazone (PGZ) on systemic and intrahepatic insulin sensitivity and on liver pathology."	3.74	Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. ( Horsmans, YJ; Lebrun, VA; Leclercq, IA; Stärkel, P, 2007)
" Insulin sensitivity of the rats was altered by adding a high-fat (HF) diet or the peroxisomal-proliferator activated receptor-gamma agonist pioglitazone to the MCD diet."	3.74	Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. ( Akahori, H; Kaneko, S; Kita, Y; Kurita, S; Matsuzawa, N; Misu, H; Nakanuma, Y; Ota, T; Sakurai, M; Takamura, T; Uno, M; Zen, Y, 2007)
"These findings suggest that long-term therapy with pioglitazone may be necessary to maintain improvements in disease activity in patients with NASH, although weight gain during treatment may ultimately limit its beneficial effects."	3.74	The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. ( Borg, B; Ghany, M; Heller, T; Hoofnagle, JH; Kleiner, DE; Liang, TJ; Loomba, R; Lutchman, G; Modi, A; Premkumar, A; Promrat, K, 2007)
" Pioglitazone can attenuate insulin resistance and biochemical and histological injury in high fat-induced fatty liver in rats."	3.73	Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. ( Li, YM; Xu, GY; Xu, L; Xu, P; Yu, CH; Zhang, XG, 2006)
" Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance."	3.72	Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004)
"Pioglitazone was well tolerated and no one discontinued due to side effects."	2.80	Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. ( Benator, D; Chairez, C; Hadigan, C; Kleiner, DE; Kovacs, JA; Matthews, L; McManus, M; Morse, CG; Nettles, MJ; Zemanick, K, 2015)
"Vitamin E vs."	2.78	Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. ( Clark, JM; Hoofnagle, JH; Kleiner, DE; Kowdley, KV; Loomba, R; Neuschwander-Tetri, BA; Sanyal, AJ; Tonascia, J; Van Natta, ML, 2013)
"Pioglitazone was more effective than glibenclamide in improving inflammation and hepatic steatosis indices."	2.78	Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. ( D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Perrone, T, 2013)
"Patients with treatment-naive type 2 diabetes (N = 16) were treated with insulin and metformin for a 3-month lead-in period, then assigned triple oral therapy (metformin, glyburide, and pioglitazone) or continued treatment with insulin and metformin."	2.77	Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. ( Duong, J; Leonard, D; Lingvay, I; Roe, ED; Szczepaniak, LS, 2012)
"Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis."	2.75	Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. ( Bass, NM; Brunt, EM; Chalasani, N; Clark, J; Diehl, AM; Hoofnagle, JH; Kleiner, DE; Kowdley, KV; Lavine, JE; McCullough, A; Neuschwander-Tetri, BA; Robuck, PR; Sanyal, AJ; Tonascia, J; Unalp, A; Van Natta, M, 2010)
"Non-alcoholic steatohepatitis (NASH) is a common liver disease associated with obesity and diabetes."	2.74	Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. ( Chalasani, NP; Hoofnagle, J; Kleiner, DE; Kowdley, KV; Robuck, PR; Sanyal, AJ; Tonascia, J; Unalp, A, 2009)
"Nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease for which there is limited therapy available."	2.73	Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. ( Aithal, GP; Austin, AS; Freeman, JG; Kaye, PV; Lawson, A; Morgan, L; Ryder, SD; Spendlove, I; Thomas, JA; Webber, J, 2008)
"Pioglitazone therapy was associated with improvements in steatosis (2."	2.72	Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. ( Ghany, MG; Heller, T; Hoofnagle, JH; Kleiner, DE; Liang, TJ; Lutchman, G; Promrat, K; Yanovski, JA, 2006)
"Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy."	2.71	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. ( Doo, E; Freedman, RJ; Ghany, M; Heller, T; Hoofnagle, JH; Kleiner, DE; Liang, TJ; Lutchman, G; Park, Y; Premkumar, A; Promrat, K; Soza, A; Uwaifo, GI; Yanovski, JA, 2004)
"Non-alcoholic fatty liver disease (NAFLD) affects one-third of the population worldwide, of which a substantial number of patients suffer from non-alcoholic steatohepatitis (NASH)."	2.61	Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. ( Boeckmans, J; Buyl, K; De Kock, J; M Rodrigues, R; Natale, A; Rogiers, V; Rombaut, M; Vanhaecke, T, 2019)
"Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western societies and a major cause of hepatic disease worldwide."	2.61	Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! ( Mikhailidis, DP; Ranjbar, G; Sahebkar, A, 2019)
"Nonalcoholic fatty liver disease (NAFLD) is prevalent in patients with obesity or type 2 diabetes."	2.55	Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. ( Bril, F; Cusi, K; Sunny, NE, 2017)
" The suggestion of this Expert Panel is that, pending forthcoming randomized clinical trials, physicians should consider using a PPARgamma agonist, such as pioglitazone, or, statin use in those with NAFLD/NASH at high CVD or HCC risk, alone and/or preferably in combination with each other or with ezetimibe, for the primary or secondary prevention of CVD, and the avoidance of cirrhosis, liver transplantation or HCC, bearing in mind that CVD is the main cause of death in NAFLD/NASH patients."	2.55	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. ( Alexandrides, TK; Athyros, VG; Bilianou, H; Cholongitas, E; Doumas, M; Elisaf, MS; Ganotakis, ES; Germanidis, G; Giouleme, O; Goudevenos, J; Karagiannis, A; Karvounis, C; Katsiki, N; Kotsis, V; Kountouras, J; Liberopoulos, E; Mantzoros, C; Mikhailidis, DP; Pitsavos, C; Polyzos, S; Rallidis, LS; Richter, D; Tsapas, AG; Tselepis, AD; Tsioufis, K; Tziomalos, K; Tzotzas, T; Vasiliadis, TG; Vlachopoulos, C, 2017)
"In patients with nonalcoholic steatohepatitis, half of deaths are due to cardiovascular disease and malignancy, yet awareness of this remains low."	2.52	Nonalcoholic fatty liver disease: a systematic review. ( Rinella, ME, 2015)
"Nonalcoholic fatty liver disease (NAFLD) is considered the most common liver disorder in the Western world."	2.49	Nonalcoholic fatty liver disease: current issues and novel treatment approaches. ( Bril, F; Cusi, K; Lomonaco, R; Sunny, NE, 2013)
"NAFLD may progress to nonalcoholic steatohepatitis (NASH) and in turn cirrhosis."	2.49	Current concepts and management approaches in nonalcoholic fatty liver disease. ( Attar, BM; Van Thiel, DH, 2013)
"Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide."	2.49	Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. ( Belfiore, A; Fruci, B; Giuliano, S; Malaguarnera, R; Mazza, A, 2013)
"When pioglitazone (n = 137) was analysed alone, the improvement in fibrosis with pioglitazone (n = 137) vs."	2.48	Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. ( Boettcher, E; Csako, G; Loomba, R; Pucino, F; Wesley, R, 2012)
"The prevalence of NAFLD is likely to increase over time due to the epidemics of obesity and diabetes."	2.48	Vitamin E and nonalcoholic fatty liver disease. ( Pacana, T; Sanyal, AJ, 2012)
"Non-invasive methods of diagnosing NAFLD without liver biopsy, using combinations of clinical history, laboratory tests and ultrasound, have been explored, but so far liver biopsy is the only proven method of distinguishing simple steatosis from NASH."	2.47	Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. ( Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N, 2011)
"Nonalcoholic steatohepatitis (NASH) is a subset of nonalcoholic fatty liver disease (NAFLD) and sometimes progresses to cirrhosis and liver failure."	2.44	Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. ( Aburatani, H; Endo, H; Fujisawa, T; Fujita, K; Hotta, K; Iwasaki, T; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Tomimoto, A; Tsutsumi, S; Wada, K; Yamamoto, S; Yoneda, K; Yoneda, M, 2007)
" Long term administration of PPARgamma activator pioglitazone ameliorated the activity of NASH."	2.43	[PPAR and NASH]. ( Aoyama, T; Tanaka, N, 2006)
"Nonalcoholic steatohepatitis (NASH), which is considered the hepatic manifestation of the metabolic syndrome is an increasingly cause of chronic liver disease in Japan."	2.43	[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. ( Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K, 2006)
"Pioglitazone also mitigated most of the steatohepatitis-related changes, however, memantine was more effective in most of the studied parameters."	1.91	A novel approach to repositioning memantine for metabolic syndrome-induced steatohepatitis: Modulation of hepatic autophagy, inflammation, and fibrosis. ( Abdel-Ghanyª, RH; Alsemehᵇ, AE; Elgharbawyª, AS; Metwallyª, SS; Zakariaª, EM, 2023)
"Metabolic dysfunction-associated steatohepatitis (MASH) is highly prevalent in type 2 diabetes (T2D)."	1.91	Prescribing of evidence-based diabetes pharmacotherapy in patients with metabolic dysfunction-associated steatohepatitis. ( Alexopoulos, AS; Batch, BC; Crowley, MJ; Moylan, C; Olsen, M; Parish, A, 2023)
"Pioglitazone treatment significantly altered levels of hepatic metabolites, including free fatty acids, lysophosphatidylcholines and phosphatidylcholines, in the liver."	1.48	Metabolomic and lipidomic analysis of the effect of pioglitazone on hepatic steatosis in a rat model of obese Type 2 diabetes. ( Jung, ES; Kim, DH; Lee, CH; Liu, KH; Park, CY; Suh, DH; Yang, H, 2018)
"Pharmacotherapy in NAFLD is not well validated, particularly combination therapy."	1.40	Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014)
"Nonalcoholic steatohepatitis (NASH) is the commonest liver disease in developed countries."	1.38	Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. ( Craig, JC; George, J; Mahady, SE; Wong, G, 2012)
"NASH, however, may progress to liver cirrhosis with risk of liver cancer."	1.38	[Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis]. ( Grønbæk, H; Heebøll, S; Kazankov, K; Poulsen, MK; Vilstrup, H, 2012)
"Pioglitazone may allow the donor indications for liver transplantation to be expanded to include severe macrovesicular fatty livers."	1.38	Decreased Mrp2 transport in severe macrovesicular fatty liver grafts. ( Aihara, A; Arii, S; Ban, D; Irie, T; Kudo, A; Nakamura, N; Ochiai, T; Tanaka, S, 2012)
"Pioglitazone was reported to improve hepatic steatosis and necroinflammation in human studies."	1.35	Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet. ( Hsiao, PJ; Hsieh, TJ; Hung, WW; Kuo, KK; Shin, SJ; Tsai, KB; Yang, CH; Yu, ML, 2008)
"The term nonalcoholic steatohepatitis (NASH) has recently been proposed to identify a fatty liver disease accompanied by diffuse fatty infiltration and inflammation."	1.34	Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. ( Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Maeyama, S; Mawatari, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Terauchi, Y; Wada, K; Yoneda, M, 2007)
"Non-alcoholic steatohepatitis (NASH) may progress to liver cirrhosis, and NASH patients with liver cirrhosis have a risk of development of hepatocellular carcinoma."	1.32	Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. ( Kawaguchi, K; Okita, K; Omori, K; Sakaida, I; Takami, T; Tsuchiya, M, 2004)

Research

Studies (87)

Authors

Clinical Trials (24)

Trial Overview

Trial Outcomes

Number of Participants With Improvement in Fibrosis

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	38 (43.68)	29.6817
2010's	46 (52.87)	24.3611
2020's	3 (3.45)	2.80

Authors	Studies
Zakariaª, EM	1
Abdel-Ghanyª, RH	1
Elgharbawyª, AS	1
Alsemehᵇ, AE	1
Metwallyª, SS	1
Alexopoulos, AS	1
Parish, A	1
Olsen, M	1
Batch, BC	1
Moylan, C	1
Crowley, MJ	1
Ranjbar, G	1
Mikhailidis, DP	2
Sahebkar, A	1
Boeckmans, J	1
Natale, A	1
Rombaut, M	1
Buyl, K	1
Rogiers, V	1
De Kock, J	1
Vanhaecke, T	1
M Rodrigues, R	1
de Zegher, F	1
Díaz, M	1
Villarroya, J	1
Cairó, M	1
López-Bermejo, A	1
Villarroya, F	1
Ibáñez, L	1
Athyros, VG	1
Alexandrides, TK	1
Bilianou, H	1
Cholongitas, E	1
Doumas, M	1
Ganotakis, ES	1
Goudevenos, J	1
Elisaf, MS	1
Germanidis, G	1
Giouleme, O	1
Karagiannis, A	1
Karvounis, C	1
Katsiki, N	1
Kotsis, V	1
Kountouras, J	1
Liberopoulos, E	1
Pitsavos, C	1
Polyzos, S	1
Rallidis, LS	1
Richter, D	1
Tsapas, AG	1
Tselepis, AD	1
Tsioufis, K	1
Tziomalos, K	1
Tzotzas, T	1
Vasiliadis, TG	1
Vlachopoulos, C	1
Mantzoros, C	1
Shen, D	1
Li, H	1
Zhou, R	1
Liu, MJ	1
Yu, H	1
Wu, DF	1
Yang, H	1
Suh, DH	1
Kim, DH	1
Jung, ES	1
Liu, KH	1
Lee, CH	1
Park, CY	1
Shawky, NM	1
Shehatou, GSG	1
Suddek, GM	1
Gameil, NM	1
Daniels, SJ	1
Leeming, DJ	1
Detlefsen, S	1
Bruun, MF	1
Hjuler, ST	1
Henriksen, K	1
Hein, P	1
Karsdal, MA	1
Brockbank, S	1
Cruwys, S	1
Maffioli, P	1
Fogari, E	1
D'Angelo, A	1
Perrone, T	1
Derosa, G	1
Attar, BM	1
Van Thiel, DH	1
Hoofnagle, JH	5
Van Natta, ML	1
Kleiner, DE	7
Clark, JM	1
Kowdley, KV	4
Loomba, R	3
Neuschwander-Tetri, BA	3
Sanyal, AJ	6
Tonascia, J	3
Takei, Y	1
Riche, DM	1
Fleming, JW	1
Malinowski, SS	1
Black, CA	1
Miller, KH	1
Wofford, MR	1
Fruci, B	1
Giuliano, S	1
Mazza, A	1
Malaguarnera, R	1
Belfiore, A	1
Zhang, W	2
Xu, YZ	1
Liu, B	2
Wu, R	2
Yang, YY	1
Xiao, XQ	1
Zhang, X	2
Surapaneni, KM	1
Jainu, M	1
Yang, L	1
Song, MQ	1
Zhang, QL	1
Shou, L	1
Zang, SF	1
Yang, YL	1
Jia, C	1
Huan, Y	1
Liu, S	2
Hou, S	1
Sun, S	1
Li, C	1
Liu, Q	1
Jiang, Q	1
Wang, Y	1
Shen, Z	1
Rinella, ME	1
Matthews, L	1
Chairez, C	1
McManus, M	1
Nettles, MJ	1
Zemanick, K	1
Morse, CG	1
Benator, D	1
Kovacs, JA	1
Hadigan, C	1
Zhu, YX	1
Zhang, ML	1
Zhong, Y	1
Wang, C	1
Jia, WP	1
Sunny, NE	2
Bril, F	2
Cusi, K	6
Xu, Z	1
Wang, G	1
Zhu, Y	1
Liu, R	1
Song, J	1
Ni, Y	1
Sun, H	1
Yang, B	1
Hou, M	1
Chen, L	1
Ji, M	1
Fu, Z	1
Aithal, GP	1
Thomas, JA	1
Kaye, PV	1
Lawson, A	1
Ryder, SD	1
Spendlove, I	1
Austin, AS	1
Freeman, JG	1
Morgan, L	1
Webber, J	1
Chalasani, NP	1
Robuck, PR	2
Hoofnagle, J	1
Unalp, A	2
Hsiao, PJ	1
Hsieh, TJ	1
Kuo, KK	1
Hung, WW	1
Tsai, KB	1
Yang, CH	1
Yu, ML	1
Shin, SJ	1
Vuppalanchi, R	1
Chalasani, N	4
Da Silva Morais, A	1
Lebrun, V	1
Abarca-Quinones, J	1
Brichard, S	1
Hue, L	1
Guigas, B	1
Viollet, B	1
Leclercq, IA	2
Czaja, MJ	1
Wierzbicki, M	1
Chabowski, A	1
Zendzian-Piotrowska, M	1
Harasim, E	1
Górski, J	1
Socha, P	2
Horvath, A	1
Vajro, P	1
Dziechciarz, P	1
Dhawan, A	1
Szajewska, H	1
Yki-Järvinen, H	1
Li, JM	1
Li, YC	1
Kong, LD	1
Hu, QH	1
McCullough, A	1
Diehl, AM	2
Bass, NM	2
Lavine, JE	1
Van Natta, M	1
Clark, J	1
Brunt, EM	2
Gastaldelli, A	3
Harrison, S	1
Belfort-Aguiar, R	1
Hardies, J	2
Balas, B	3
Schenker, S	4
Brouwers, MC	1
de Graaf, J	1
van Greevenbroek, MM	1
Schaper, N	1
Stehouwer, CD	1
Stalenhoef, AF	1
Harrison, SA	3
Zaitone, S	1
Hassan, N	1
El-Orabi, N	1
El-Awady, el-S	1
Smith, BW	1
Adams, LA	2
Samson, SL	1
Sathyanarayana, P	1
Jogi, M	1
Gonzalez, EV	1
Gutierrez, A	1
Krishnamurthy, R	1
Muthupillai, R	1
Chan, L	1
Bajaj, M	1
Boettcher, E	1
Csako, G	1
Pucino, F	1
Wesley, R	1
Shyangdan, D	1
Clar, C	1
Ghouri, N	1
Henderson, R	1
Gurung, T	1
Preiss, D	1
Sattar, N	1
Fraser, A	1
Waugh, N	1
Heebøll, S	1
Kazankov, K	1
Poulsen, MK	1
Vilstrup, H	1
Grønbæk, H	1
Fujimoto, M	1
Tsuneyama, K	1
Fujimoto, T	1
Selmi, C	1
Gershwin, ME	1
Shimada, Y	1
Kawai, D	1
Takaki, A	1
Nakatsuka, A	1
Wada, J	1
Tamaki, N	1
Yasunaka, T	1
Koike, K	2
Tsuzaki, R	1
Matsumoto, K	1
Miyake, Y	1
Shiraha, H	1
Morita, M	1
Makino, H	1
Yamamoto, K	1
Janczyk, W	1
Bell, LN	1
Wang, J	1
Muralidharan, S	1
Chalasani, S	1
Fullenkamp, AM	1
Wilson, LA	1
McCullough, AJ	2
Unalp-Arida, A	1
Kudo, A	1
Ban, D	1
Aihara, A	1
Irie, T	1
Ochiai, T	1
Nakamura, N	1
Tanaka, S	1
Arii, S	1
Mahady, SE	1
Wong, G	1
Craig, JC	1
George, J	1
Lingvay, I	1
Roe, ED	1
Duong, J	1
Leonard, D	1
Szczepaniak, LS	1
Zhao, JS	1
Zhu, FS	1
Yang, CQ	1
Chen, XM	1
Ohki, T	1
Isogawa, A	1
Iwamoto, M	1
Ohsugi, M	1
Yoshida, H	1
Toda, N	1
Tagawa, K	1
Omata, M	1
Pacana, T	1
Zhang, F	1
Xu, Y	1
Yang, Y	1
Zhou, H	1
Wang, L	1
Wan, K	1
Xiao, X	1
Lomonaco, R	1
Satoh, H	1
Ide, N	1
Kagawa, Y	1
Maeda, T	1
Füessl, HS	1
Itoh, S	1
Kanazuka, A	1
Akimoto, T	1
Promrat, K	3
Lutchman, G	3
Uwaifo, GI	1
Freedman, RJ	1
Soza, A	1
Heller, T	3
Doo, E	1
Ghany, M	2
Premkumar, A	2
Park, Y	1
Liang, TJ	3
Yanovski, JA	2
Kawaguchi, K	2
Sakaida, I	2
Tsuchiya, M	1
Omori, K	1
Takami, T	1
Okita, K	1
Shadid, S	1
Jensen, MD	1
Prasithsirikul, W	1
Bunnag, P	1
Angulo, P	1
Mofrad, PS	1
Contos, MJ	1
Sargeant, C	1
Luketic, VA	1
Sterling, RK	1
Stravitz, RT	1
Shiffman, ML	1
Clore, J	1
Mills, AS	1
Siebler, J	1
Galle, PR	1
Tanaka, N	1
Aoyama, T	1
Korenaga, M	1
Korenaga, K	1
Uchida, K	1
Ghany, MG	1
Xu, P	2
Zhang, XG	1
Li, YM	2
Yu, CH	2
Xu, L	2
Xu, GY	2
Yoneda, M	3
Fujita, K	3
Nakajima, A	3
Wada, K	3
Lebrun, VA	1
Stärkel, P	1
Horsmans, YJ	1
Belfort, R	2
Brown, K	1
Darland, C	2
Finch, J	2
Tio, F	1
Pulcini, J	1
Berria, R	1
Ma, JZ	1
Dwivedi, S	1
Havranek, R	1
Fincke, C	1
DeFronzo, R	1
Bannayan, GA	1
Ota, T	2
Takamura, T	2
Kurita, S	1
Matsuzawa, N	1
Kita, Y	1
Uno, M	1
Akahori, H	1
Misu, H	1
Sakurai, M	1
Zen, Y	1
Nakanuma, Y	1
Kaneko, S	2
Targher, G	1
Chavez-Tapia, NC	1
Barrientos-Gutierrez, T	1
Uribe, M	1
Lang, L	1
Mawatari, H	1
Takahashi, H	2
Kirikoshi, H	1
Inamori, M	1
Nozaki, Y	2
Maeyama, S	1
Saito, S	2
Iwasaki, T	2
Terauchi, Y	1
Modi, A	1
Borg, B	1
Pfützner, A	1
Weber, MM	1
Forst, T	1
Endo, H	1
Tomimoto, A	1
Fujisawa, T	1
Yoneda, K	1
Yamamoto, S	1
Tsutsumi, S	1
Aburatani, H	1
Hotta, K	1
Khashab, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Clinical Research Network in Nonalcoholic Steatohepatitis: Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)[NCT00063622]	Phase 3	247 participants (Actual)	Interventional	2005-01-31	Completed
The Role of Microbiome Reprogramming on Liver Fat Accumulation[NCT03914495]		57 participants (Actual)	Interventional	2019-05-21	Terminated (stopped due to PI carefully considered multiple factors and decided to close study to any further enrollment.)
Metabolic Surgery for the Treatment and Understanding of Non-Alcoholic Steato-Hepatitis (NASH): Weight-Dependent and Weight-Independent Effects[NCT04282005]		28 participants (Anticipated)	Interventional	2020-02-13	Recruiting
Predictors of Improvement of Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients Undergoing Bariatric Surgery[NCT04059029]		200 participants (Anticipated)	Observational	2016-10-31	Enrolling by invitation
Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet[NCT03141008]		54 participants (Actual)	Observational	2017-09-15	Completed
Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection[NCT00742326]	Phase 4	13 participants (Actual)	Interventional	2008-08-31	Terminated (stopped due to Enrollment stopped prior to complete enrollment due to slow accrual)
Effect of Low-Dose Pioglitazone in Patients With Nonalcoholic Steatohepatitis (NASH)[NCT04501406]	Phase 2	166 participants (Anticipated)	Interventional	2020-12-15	Recruiting
The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study[NCT03222206]	Phase 4	34 participants (Actual)	Interventional	2017-11-08	Completed
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572]	Phase 4	120 participants (Anticipated)	Interventional	2017-08-16	Recruiting
Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571]		1,080 participants (Anticipated)	Observational	2019-04-01	Recruiting
A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis[NCT01950884]	Phase 4	45 participants (Anticipated)	Interventional	2013-10-31	Enrolling by invitation
Efficacy of Nutritional Therapy With High Methionine Content in the Treatment of Non-alcoholic Fatty Liver: a Randomized Clinical Trial[NCT04450875]		121 participants (Actual)	Interventional	2015-03-24	Completed
A Single-arm, Open-label Clinical Study to Evaluate the Effect of SIM01 in Female Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)[NCT05885373]		40 participants (Anticipated)	Interventional	2023-03-01	Recruiting
An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease[NCT01720719]	Phase 4	120 participants (Anticipated)	Interventional	2013-05-31	Recruiting
Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus[NCT01432405]	Phase 4	24 participants (Actual)	Interventional	2007-06-30	Completed
Effect of a Systematic Physical Exercise Program and Spirulina Maxima Supplementation on the Body Composition, Physical Function and Blood Lipid Profile in Sedentary Older Adults With Excess Weight[NCT04658875]		52 participants (Anticipated)	Interventional	2022-01-17	Not yet recruiting
Role of Exenatide in Treatment of NASH-a Pilot Study[NCT00650546]	Phase 2/Phase 3	8 participants (Actual)	Interventional	2006-08-31	Completed
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)[NCT00227110]	Phase 4	55 participants (Actual)	Interventional	2002-10-31	Completed
Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease - A Randomized Controlled Trial[NCT00868933]		159 participants (Actual)	Interventional	2009-02-28	Completed
A Randomized,Placebo-controlled,Double-blind Trial of Phyllanthus Urinaria (Hepaguard®) in Adults With Nonalcoholic Steatohepatitis[NCT01210989]		60 participants (Actual)	Interventional	2010-05-31	Completed
Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease[NCT03459079]	Phase 2	54 participants (Anticipated)	Interventional	2018-08-14	Recruiting
[NCT00870012]		20 participants (Actual)	Interventional	2009-02-28	Completed
Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis[NCT05605158]	Phase 3	56 participants (Anticipated)	Interventional	2022-11-30	Not yet recruiting
Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus[NCT00633282]	Phase 2	184 participants (Actual)	Interventional	2008-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score, which indicates improvement in fibrosis. (NCT00063622)
Timeframe: baseline and 96 weeks

Number of Participants With Improvement in Hepatocellular Ballooning

Intervention	participants (Number)
Pioglitazone	31
Vitamin E	33
Placebo	22

Hepatocellular ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe hepatocellular ballooning. This secondary outcome measure is the number of participants that experienced a decrease in hepatocellular ballooning score, which indicates improvement in hepatocellular ballooning. (NCT00063622)
Timeframe: baseline and 96 weeks

Number of Participants With Improvement in Lobular Inflammation

Intervention	participants (Number)
Pioglitazone	31
Vitamin E	40
Placebo	21

Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score, which indicates improvement in lobular inflammation. (NCT00063622)
Timeframe: baseline and 96 weeks

Number of Participants With Improvement in Non-alcoholic Fatty Liver Disease (NAFLD) Activity Defined by Change in Standardized Scoring of Liver Biopsies at Baseline and After 96 Weeks of Treatment.

Intervention	participants (Number)
Pioglitazone	41
Vitamin E	43
Placebo	25

Total nonalcoholic fatty liver disease (NAFLD) activity was assessed on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (assessed on a scale of 0 to 3), lobular inflammation (assessed on a scale of 0 to 3), and hepatocellular ballooning (assessed on a scale of 0 to 2). The primary outcome was an improvement in histological findings from baseline to 96 weeks, which required an improvement by 1 or more points in the hepatocellular ballooning score; no increase in the fibrosis score; and either a decrease in the activity score for nonalcoholic fatty liver disease to a score of 3 or less or a decrease in the activity score of at least 2 points, with at least a 1-point decrease in either the lobular inflammation or steatosis score. (NCT00063622)
Timeframe: baseline and 96 weeks

Number of Participants With Improvement in Steatosis

Intervention	participants (Number)
Pioglitazone	27
Vitamin E	36
Placebo	16

Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score, which indicates improvement in steatosis. (NCT00063622)
Timeframe: baseline and 96 weeks

Number of Participants With Resolution of Definite Nonalcoholic Steatohepatitis

Intervention	participants (Number)
Pioglitazone	48
Vitamin E	43
Placebo	22

The criteria for nonalcoholic steatohepatitis was definite or possible steatohepatitis (assessed by a pathologist) with an activity score of 5 or more, or definite steatohepatitis (confirmed by two pathologists) with an activity score of 4. This secondary outcome measure is the number of participants who met this definition at baseline and did not meet this definition after 96 weeks of treatment and thus had a resolution of steatohepatitis. (NCT00063622)
Timeframe: baseline and 96 weeks

Change in Hepatic Steatosis and Hepatic Inflammation/Fibrosis in HIV/HCV Co-infected Patients With Steatosis.

Intervention	participants (Number)
Pioglitazone	33
Vitamin E	29
Placebo	15

Change in hepatic steatosis and hepatic inflammation/fibrosis in HIV/HCV co-infected patients with steatosis. Change in Hepatic Fat Content measured by MR spectroscopy: 48 weeks compared to Baseline (NCT00742326)
Timeframe: 48 weeks

Change in Insulin Resistance in HIV- and HCV-infected Patients With Steatosis Compared to Placebo

Intervention	percentage of hepatic fat on MRS (Mean)
Pioglitazone	-7.43
Placebo	-2.17

Change in Glucose Area Under the Curve from standard oral glucose challenge ( baseline to 2 hours): Week 48 - Baseline values (NCT00742326)
Timeframe: 48 weeks

Hepatic Fat

Intervention	mg*120 minutes/dL (Mean)
Pioglitazone	-31
Placebo	11

The effect of exenatide and pioglitazone on liver fat content after one year of treatment in patients with type 2 diabetes. (NCT01432405)
Timeframe: one year

Plasma Adipocytokines

Intervention	percent of liver fat (Mean)
Pioglitazone and Exenatide	4.7
Pioglitazone	6.5

the effect of the intervention on plasma adiponectin levels. (NCT01432405)
Timeframe: one year

Change in NAS

Intervention	microgram per ml (Mean)
Pioglitazone and Exenatide	23.2
Pioglitazone	15.8

The NAFLD Activity Score (NAS) is an underweight sum of steatosis (score 0-3), inflammation (score 0-3), ballooning scores (0-2). The NAS can range from 0-8 with the higher score indicating more aggressive disease. (NCT00650546)
Timeframe: Between baseline and 28 weeks of treatment with exenatide, sub q, 5-10 mcq.

Number of Patients With Improvement in Liver Histology After Treatment With Exenatide

Intervention	units on a scale (Mean)
Individuals Who Recieved Treatment With Exenatide	-1.5

Number of patients with liver histology improved with exenatide. The improvement of liver histology was defined as (1) no worsening of the fibrosis score, (11) improved score by at least one point in hepatocyte ballooning, and (111) either (a) improvement in NAS (NAFLD Activity Score) by two points spread across as least two of the three NAS components, or by (B)post-treatment NAS<3. (NCT00650546)
Timeframe: between baseline and 24-28 weeks after initiating treatment

Article	Year
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Metabolism: clinical and experimental, 2019, Volume: 101 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Glucagon-Like Peptide 1;	2019
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Cells, 2019, 12-21, Volume: 9, Issue:1 Topics: Chalcones; Diabetes Mellitus, Type 2; Drug Development; Fatty Liver; Humans; Hypoglycemic Agents; In	2019
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: clinical and experimental, 2017, Volume: 71 Topics: Animals; Cardiovascular Diseases; Drug Therapy, Combination; Fatty Liver; Humans; Hydroxymethylgluta	2017
Current concepts and management approaches in nonalcoholic fatty liver disease. TheScientificWorldJournal, 2013, Volume: 2013 Topics: Cognitive Behavioral Therapy; Diet Therapy; Exercise Therapy; Fatty Liver; Humans; Hypoglycemic Agen	2013
Treatment of non-alcoholic fatty liver disease. Journal of gastroenterology and hepatology, 2013, Volume: 28 Suppl 4 Topics: Animals; Fatty Liver; Humans; Inflammation; Insulin Resistance; Life Style; Liver Transplantation; M	2013
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. International journal of molecular sciences, 2013, Nov-20, Volume: 14, Issue:11 Topics: Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Re	2013
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, Jun-09, Volume: 313, Issue:22 Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live	2015
Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. Trends in endocrinology and metabolism: TEM, 2017, Volume: 28, Issue:4 Topics: Animals; Fatty Liver; Glucagon-Like Peptide 1; Humans; Mitochondria; Non-alcoholic Fatty Liver Disea	2017
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:1 Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type	2009
Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. Journal of pediatric gastroenterology and nutrition, 2009, Volume: 48, Issue:5 Topics: Acetylcysteine; Adult; Alanine Transaminase; Aspartate Aminotransferases; Carnitine; Child; Dietary	2009
Thiazolidinediones and the liver in humans. Current opinion in lipidology, 2009, Volume: 20, Issue:6 Topics: Diabetes Mellitus, Type 2; Fats; Fatty Liver; Humans; Hypoglycemic Agents; Lipid Metabolism; Liver;	2009
Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus. Current opinion in lipidology, 2010, Volume: 21, Issue:6 Topics: Adipose Tissue; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Discovery; Fatty Liver; Genetic Pr	2010
Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nature reviews. Endocrinology, 2011, May-10, Volume: 7, Issue:8 Topics: Diabetes Mellitus, Type 2; Fatty Liver; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Diseas	2011
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:1 Topics: Fatty Liver; Humans; Hypoglycemic Agents; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease;	2012
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:38 Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents;	2011
Vitamin E and nonalcoholic fatty liver disease. Current opinion in clinical nutrition and metabolic care, 2012, Volume: 15, Issue:6 Topics: Alanine Transaminase; Animals; Antioxidants; Diabetes Mellitus; Disease Models, Animal; Dose-Respons	2012
Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs, 2013, Volume: 73, Issue:1 Topics: Carcinoma, Hepatocellular; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Non-alcohol	2013
Treatment of nonalcoholic fatty liver disease. World journal of gastroenterology, 2006, Apr-14, Volume: 12, Issue:14 Topics: Alanine Transaminase; Animals; Antioxidants; Body Mass Index; Fatty Liver; Humans; Hypolipidemic Age	2006
[PPAR and NASH]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:6 Topics: Acyl-CoA Oxidase; Animals; Cytokines; Fatty Liver; Gene Deletion; Humans; Inflammation Mediators; In	2006
[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:6 Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglit	2006
[PPAR gamma ligand pioglitazone as a therapeutic strategy in nonalcoholic steatohepatitis (NASH)]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2006, Volume: 128, Issue:4 Topics: Fatty Liver; Humans; Hypoglycemic Agents; Ligands; Pioglitazone; PPAR gamma; Thiazolidinediones	2006
Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:12 Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatt	2007
Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. Journal of pharmacological sciences, 2007, Volume: 105, Issue:2 Topics: Alanine Transaminase; Fatty Liver; Gene Expression Profiling; Gene Expression Regulation; Humans; Hy	2007
Use of insulin sensitizers in NASH. Endocrinology and metabolism clinics of North America, 2007, Volume: 36, Issue:4 Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metform	2007

Article	Year
The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat. Scientific reports, 2021, 03-29, Volume: 11, Issue:1 Topics: Adolescent; Adult; Case-Control Studies; Child; Fatty Liver; Female; Growth Differentiation Factor 1	2021
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:9 Topics: Adipokines; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2	2013
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:2 Topics: Adult; Alanine Transaminase; Antioxidants; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; M	2013
Effect of piglitazone and metformin on retinol-binding protein-4 and adiponectin in patients with type 2 diabetes mellitus complicated with non-alcohol fatty acid liver diseases. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2014, Volume: 36, Issue:3 Topics: Adiponectin; Adult; Aged; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Male; Metformin; M	2014
Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. AIDS research and human retroviruses, 2015, Volume: 31, Issue:10 Topics: Adult; Coinfection; Double-Blind Method; Fatty Liver; Female; Hepatitis C, Chronic; Histocytochemist	2015
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 2008, Volume: 135, Issue:4 Topics: Adipokines; Adult; Aged; Alkaline Phosphatase; Fatty Liver; Female; Humans; Hypoglycemic Agents; Ins	2008
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 2008, Volume: 135, Issue:4 Topics: Adipokines; Adult; Aged; Alkaline Phosphatase; Fatty Liver; Female; Humans; Hypoglycemic Agents; Ins	2008
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 2008, Volume: 135, Issue:4 Topics: Adipokines; Adult; Aged; Alkaline Phosphatase; Fatty Liver; Female; Humans; Hypoglycemic Agents; Ins	2008
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 2008, Volume: 135, Issue:4 Topics: Adipokines; Adult; Aged; Alkaline Phosphatase; Fatty Liver; Female; Humans; Hypoglycemic Agents; Ins	2008
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemporary clinical trials, 2009, Volume: 30, Issue:1 Topics: Antioxidants; Double-Blind Method; Fatty Liver; Humans; Hypoglycemic Agents; Pioglitazone; Research	2009
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemporary clinical trials, 2009, Volume: 30, Issue:1 Topics: Antioxidants; Double-Blind Method; Fatty Liver; Humans; Hypoglycemic Agents; Pioglitazone; Research	2009
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemporary clinical trials, 2009, Volume: 30, Issue:1 Topics: Antioxidants; Double-Blind Method; Fatty Liver; Humans; Hypoglycemic Agents; Pioglitazone; Research	2009
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemporary clinical trials, 2009, Volume: 30, Issue:1 Topics: Antioxidants; Double-Blind Method; Fatty Liver; Humans; Hypoglycemic Agents; Pioglitazone; Research	2009
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 2010, May-06, Volume: 362, Issue:18 Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo	2010
Pioglitazone in the treatment of NASH: the role of adiponectin. Alimentary pharmacology & therapeutics, 2010, Volume: 32, Issue:6 Topics: Adiponectin; Adult; Case-Control Studies; Fatty Liver; Glucose Tolerance Test; Humans; Hypoglycemic	2010
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia, 2011, Volume: 54, Issue:12 Topics: Adult; Aged; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy,	2011
Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:4 Topics: Adipose Tissue; Adult; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administratio	2012
Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2012, Volume: 60, Issue:7 Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Fema	2012
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.), 2004, Volume: 39, Issue:1 Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Female; Glucose Tolerance Tes	2004
Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2003, Volume: 1, Issue:5 Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Female; Glucose Tolerance Tes	2003
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004, Volume: 2, Issue:12 Topics: 3-Hydroxybutyric Acid; Alanine Transaminase; Antioxidants; Drug Therapy, Combination; Fatty Acids, N	2004
Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2006, Volume: 4, Issue:8 Topics: Adiponectin; Adult; Biopsy; Cytokines; Fatty Liver; Female; Humans; Hypoglycemic Agents; Leptin; Liv	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. Journal of hepatology, 2007, Volume: 47, Issue:4 Topics: Adipose Tissue; Blood Glucose; Body Water; Fatty Liver; Female; Hepatitis; Humans; Hypoglycemic Agen	2007
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. Journal of hepatology, 2007, Volume: 47, Issue:4 Topics: Adipose Tissue; Blood Glucose; Body Water; Fatty Liver; Female; Hepatitis; Humans; Hypoglycemic Agen	2007
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. Journal of hepatology, 2007, Volume: 47, Issue:4 Topics: Adipose Tissue; Blood Glucose; Body Water; Fatty Liver; Female; Hepatitis; Humans; Hypoglycemic Agen	2007
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. Journal of hepatology, 2007, Volume: 47, Issue:4 Topics: Adipose Tissue; Blood Glucose; Body Water; Fatty Liver; Female; Hepatitis; Humans; Hypoglycemic Agen	2007

Article	Year
A novel approach to repositioning memantine for metabolic syndrome-induced steatohepatitis: Modulation of hepatic autophagy, inflammation, and fibrosis. Life sciences, 2023, Apr-15, Volume: 319 Topics: Animals; Autophagy; Fatty Liver; Fibrosis; Inflammation; Lipids; Liver; Male; Memantine; Metabolic S	2023
Prescribing of evidence-based diabetes pharmacotherapy in patients with metabolic dysfunction-associated steatohepatitis. BMJ open diabetes research & care, 2023, Nov-29, Volume: 11, Issue:6 Topics: Aged; Black or African American; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Ethnicity; Fatt	2023
Pioglitazone attenuates aging-related disorders in aged apolipoprotein E deficient mice. Experimental gerontology, 2018, Volume: 102 Topics: Age Factors; Aging; Animals; Anti-Inflammatory Agents; Antioxidants; Aortic Diseases; Atherosclerosi	2018
Metabolomic and lipidomic analysis of the effect of pioglitazone on hepatic steatosis in a rat model of obese Type 2 diabetes. British journal of pharmacology, 2018, Volume: 175, Issue:17 Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; Hypoglycemic Agents; Lipid	2018
Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. Environmental toxicology and pharmacology, 2019, Volume: 66 Topics: Animals; Aorta, Thoracic; Blood Glucose; Body Weight; C-Reactive Protein; Dyslipidemias; Fatty Liver	2019
Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 111 Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Diet, High-F	2019
Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. The Annals of pharmacotherapy, 2014, Volume: 48, Issue:1 Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Drug Resistance; Drug	2014
Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. TheScientificWorldJournal, 2014, Volume: 2014 Topics: Adipose Tissue; Angiotensin-Converting Enzyme 2; Animals; Diet, High-Fat; Fatty Liver; Gene Expressi	2014
Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2014, Volume: 65, Issue:1 Topics: Animals; Antioxidants; Catalase; Citrates; Diet, High-Fat; Fatty Liver; Glutathione; Glutathione Per	2014
Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice. International journal of molecular sciences, 2015, May-29, Volume: 16, Issue:6 Topics: Animals; Fatty Liver; Gene Expression Profiling; Gene Expression Regulation; Hypoglycemic Agents; Li	2015
Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver. Journal of diabetes research, 2016, Volume: 2016 Topics: Animals; Diet, High-Fat; Fatty Liver; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents	2016
PPAR-γ agonist ameliorates liver pathology accompanied by increasing regulatory B and T cells in high-fat-diet mice. Obesity (Silver Spring, Md.), 2017, Volume: 25, Issue:3 Topics: Animals; B-Lymphocytes; Cholesterol; Diet, High-Fat; Fatty Liver; Interleukin-10; Intra-Abdominal Fa	2017
Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet. BMC molecular biology, 2008, Sep-26, Volume: 9 Topics: Animals; Antioxidants; Dietary Fats; DNA Damage; DNA Glycosylases; DNA Repair; Fatty Liver; Guanosin	2008
Prevention of steatohepatitis by pioglitazone: implication of adiponectin-dependent inhibition of SREBP-1c and inflammation. Journal of hepatology, 2009, Volume: 50, Issue:3 Topics: Adiponectin; AMP-Activated Protein Kinase Kinases; Animals; Choline Deficiency; DNA Primers; Fatty L	2009
Pioglitazone: more than just an insulin sensitizer. Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:5 Topics: Animals; Fatty Liver; Hepatectomy; Hypoglycemic Agents; Insulin Resistance; Liver Regeneration; Obes	2009
Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding. Advances in medical sciences, 2009, Volume: 54, Issue:1 Topics: Animals; Dietary Fats; Fatty Acids; Fatty Acids, Nonesterified; Fatty Liver; Lipid Metabolism; Lipid	2009
Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats. Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:5 Topics: Animals; Curcumin; Dietary Carbohydrates; Extracellular Signal-Regulated MAP Kinases; Fatty Liver; F	2010
Insulin sensitizers in nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:4 Topics: Clinical Trials as Topic; Fatty Liver; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Non	2011
Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease. European journal of pharmacology, 2011, Jul-15, Volume: 662, Issue:1-3 Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Biomarkers; Body Weight; C	2011
[Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis]. Ugeskrift for laeger, 2012, Feb-20, Volume: 174, Issue:8 Topics: Fatty Liver; Humans; Hypoglycemic Agents; Liver Cirrhosis; Liver Neoplasms; Pioglitazone; Prognosis;	2012
Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:9 Topics: Animals; Cell Aggregation; Cholesterol; Disease Models, Animal; Fatty Acids, Nonesterified; Fatty Li	2012
Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:3 Topics: Animals; Disease Progression; Fatty Liver; Hydrogen; Hypoglycemic Agents; Liver Neoplasms; Male; Mic	2012
Non-alcoholic fatty liver disease in children. Clinics and research in hepatology and gastroenterology, 2012, Volume: 36, Issue:3 Topics: Biopsy; Child; Fatty Liver; Humans; Hypoglycemic Agents; Life Style; Liver; Metformin; Obesity; Piog	2012
Decreased Mrp2 transport in severe macrovesicular fatty liver grafts. The Journal of surgical research, 2012, Volume: 178, Issue:2 Topics: Animals; ATP-Binding Cassette Transporters; Bile; Choline Deficiency; Cyclic AMP-Dependent Protein K	2012
Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:6 Topics: Combined Modality Therapy; Cost-Benefit Analysis; Fatty Liver; Humans; Hypoglycemic Agents; Life Sty	2012
Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats. Chinese medical journal, 2012, Volume: 125, Issue:13 Topics: Alanine Transaminase; Animals; Cyclooxygenase 2; Fatty Liver; Glutathione Peroxidase; Male; Malondia	2012
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. TheScientificWorldJournal, 2012, Volume: 2012 Topics: Adult; Alanine Transaminase; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Dru	2012
Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. Clinical and experimental pharmacology & physiology, 2012, Volume: 39, Issue:12 Topics: Animals; Body Weight; Cyclic AMP-Dependent Protein Kinases; Diet, High-Fat; Fatty Liver; Hypoglycemi	2012
Hepatic steatosis with relation to increased expression of peroxisome proliferator-activated receptor-γ in insulin resistant mice. Biological & pharmaceutical bulletin, 2013, Volume: 36, Issue:4 Topics: Animals; Fatty Liver; Gene Expression; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistan	2013
[Fatty liver. Not only ultrasound to be relied on!]. MMW Fortschritte der Medizin, 2003, Sep-25, Volume: 145, Issue:39 Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Fatty Liver; Female; Hepatitis; Hepatitis C; Hep	2003
Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis. Digestive diseases and sciences, 2003, Volume: 48, Issue:11 Topics: Aged; Cholagogues and Choleretics; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver	2003
Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochemical and biophysical research communications, 2004, Feb-27, Volume: 315, Issue:1 Topics: Amino Acids; Animal Feed; Animals; Biomarkers; Body Weight; Choline Deficiency; Fatty Liver; Fibrosi	2004
Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87, Issue:2 Topics: Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Sch	2004
Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers? Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004, Volume: 2, Issue:12 Topics: 3-Hydroxybutyric Acid; Alanine Transaminase; Antioxidants; Drug Therapy, Combination; Fatty Acids, N	2004
Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. Journal of Zhejiang University. Science. B, 2006, Volume: 7, Issue:8 Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Fatty Liver; Insul	2006
[Preventive effects of pioglitazone on rat fatty liver induced by a high fat diet]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2006, Volume: 14, Issue:9 Topics: Animals; Dietary Fats; Fatty Liver; Hypoglycemic Agents; Male; Pioglitazone; Rats; Rats, Sprague-Daw	2006
Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. Laboratory investigation; a journal of technical methods and pathology, 2007, Volume: 87, Issue:1 Topics: Animals; Blood Glucose; Disease Models, Animal; Fatty Liver; Female; Hepatitis, Chronic; Hypoglycemi	2007
Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Diabetes Mellitus, Type 2; Fatty Liver; Hepatitis; Humans; Hypoglycemic Agents; Insulin Resistance;	2006
Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology, 2007, Volume: 132, Issue:1 Topics: Animal Feed; Animals; Choline; Collagen Type I; Collagen Type I, alpha 1 Chain; Diabetes Mellitus, T	2007
Pioglitazone in nonalcoholic steatohepatitis. The New England journal of medicine, 2007, Mar-08, Volume: 356, Issue:10 Topics: Diabetes Mellitus, Type 2; Fatty Liver; Glucose Intolerance; Humans; Hypoglycemic Agents; Liver; Pio	2007
Pioglitazone in nonalcoholic steatohepatitis. The New England journal of medicine, 2007, Mar-08, Volume: 356, Issue:10 Topics: Diet, Reducing; Exercise Therapy; Fatty Liver; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidi	2007
Pioglitazone in nonalcoholic steatohepatitis. The New England journal of medicine, 2007, Mar-08, Volume: 356, Issue:10 Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; H	2007
Pioglitazone trial for NASH: results show promise. Gastroenterology, 2007, Volume: 132, Issue:3 Topics: Caloric Restriction; Combined Modality Therapy; Fatty Liver; Hepatitis; Humans; Hypoglycemic Agents;	2007
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Digestive diseases and sciences, 2007, Volume: 52, Issue:12 Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; B	2007
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:2 Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Female; Humans; Insulin Resis	2007
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:2 Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Female; Humans; Insulin Resis	2007
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:2 Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Female; Humans; Insulin Resis	2007
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:2 Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Female; Humans; Insulin Resis	2007

pioglitazone and Liver Steatosis